» Articles » PMID: 39065058

Utilizing Feline Lentiviral Infection to Establish a Translational Model for COVID-19 in People with Human Immunodeficiency Virus Infection

Overview
Journal Microorganisms
Specialty Microbiology
Date 2024 Jul 27
PMID 39065058
Authors
Affiliations
Soon will be listed here.
Abstract

People living with human immunodeficiency virus (PLWH) are a significant population globally. Research delineating our understanding of coinfections in PLWH is critical to care for those navigating infection with other pathogens. The recent COVID-19 pandemic underscored the urgent need for studying the effects of SARS-CoV-2 infections in therapy-controlled and uncontrolled immunodeficiency viral infections. This study established the utility of a feline model for the in vivo study of coinfections. Domestic cats are naturally infected with SARS-CoV-2 and Feline Immunodeficiency Virus, a lentivirus molecularly and pathogenically similar to HIV. In this study, comparisons are made between FIV-positive and FIV-negative cats inoculated with SARS-CoV-2 (B.1.617.2.) in an experimental setting. Of the FIV+ cats, three received Zidovudine (AZT) therapy in the weeks leading up to SARS-CoV-2 inoculation, and two did not. SARS-CoV-2 viral RNA was quantified, histopathologic comparisons of respiratory tissues were made, and T-cell populations were analyzed for immune phenotype shifts between groups. CD4+ T lymphocyte responses varied, with FIV+-untreated cats having the poorest CD4+ response to SARS-CoV-2 infection. While all cats had significant pulmonary inflammation, key histopathologic features of the disease differed between groups. Additionally, viral genomic analysis was performed, and results were analyzed for the presence of emerging, absent, amplified, or reduced mutations in SARS-CoV-2 viral RNA after passage through the feline model. Positive selection is noted, especially in FIV+ cats untreated with AZT, and mutations with potential relevance were identified; one FIV+-untreated cat had persistent, increasing SARS-CoV-2 RNA in plasma five days post-infection. These findings and others support the utility of the feline model for studying coinfection in people with HIV and highlight the importance of antiretroviral therapy in clearing SARS-CoV-2 coinfections to minimize transmission and emergence of mutations that may have deleterious effects.

References
1.
Nomah D, Reyes-Uruena J, Diaz Y, Moreno S, Aceiton J, Bruguera A . Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV. 2021; 8(11):e701-e710. PMC: 8514194. DOI: 10.1016/S2352-3018(21)00240-X. View

2.
Patel R, Pella P . COVID-19 in a patient with HIV infection. J Med Virol. 2020; 92(11):2356-2357. PMC: 7280676. DOI: 10.1002/jmv.26049. View

3.
Polak S, Van Gool I, Cohen D, von der Thusen J, van Paassen J . A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. 2020; 33(11):2128-2138. PMC: 7306927. DOI: 10.1038/s41379-020-0603-3. View

4.
Falcone M, Suardi L, Tiseo G, Barbieri C, Giusti L, Galfo V . Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19. Clin Ther. 2022; 44(3):364-373. PMC: 8761549. DOI: 10.1016/j.clinthera.2022.01.007. View

5.
Kornya M, Kornya M, Little S, Scherk M, Sears W, Bienzle D . Association between oral health status and retrovirus test results in cats. J Am Vet Med Assoc. 2014; 245(8):916-22. DOI: 10.2460/javma.245.8.916. View